lower
respiratori
tract
infect
high
morbid
mortal
immunocompromis
patient
rano
et
al
boersma
et
al
hummel
et
al
identif
caus
agent
may
influenc
previous
introduc
empir
antimicrobi
therapi
enabl
administr
specif
therapi
avail
oren
et
al
hohenadel
et
al
hummel
et
al
patient
hematolog
malign
increas
risk
opportunist
infect
invas
mycos
pneumocysti
jirovecii
pneumonia
pcp
cytomegaloviru
cmv
pneumonia
rano
et
al
joo
et
al
common
viral
infect
upper
respiratori
tract
high
tendenc
progress
toward
sever
pneumonia
result
high
mortal
rate
estim
patient
infect
frequent
associ
bacteri
fungal
coinfect
andor
superinfect
chemali
et
al
bronchoalveolar
lavag
bal
valuabl
uniformli
accept
safe
procedur
chemali
et
al
joo
et
al
kuehnhardt
et
al
may
identifi
etiolog
agent
pulmonari
infect
aim
studi
evalu
diagnost
yield
microbiolog
bal
fluid
balf
analysi
patient
malign
hematolog
disord
use
diagnost
method
includ
pcr
furthermor
evalu
clinic
relev
cutoff
two
import
opportunist
pathogen
pneumocysti
jirovecii
dna
quantiti
diagnosi
pcp
galactomannan
gm
aspergillu
index
balf
diagnosi
invas
aspergillosi
ia
descript
statist
demograph
baselin
characterist
summar
patient
number
percentag
patient
categori
summar
categor
variabl
categor
data
analyz
use
chisquar
test
fisher
exact
test
use
conting
tabl
unpair
test
nonparametr
mannwhitney
rank
sum
test
use
analysi
independ
group
p
valu
consid
statist
signific
roc
curv
calcul
pneumocysti
jirovecii
qpcr
gm
index
statist
analys
perform
use
softwar
sigmaplot
window
version
systat
softwar
medcalc
v
medcalc
belgium
total
balf
sampl
patient
femal
male
analyz
median
age
time
balf
collect
year
rang
patient
repeat
bal
median
interv
procedur
day
interquartil
rang
iqr
day
common
underli
diseas
nonhodgkin
lymphoma
acut
myeloid
leukemia
twentynin
percent
sampl
balf
sampl
obtain
neutropen
patient
examin
bal
patient
done
recipi
allogen
hematopoiet
stem
cell
transplant
hsct
patient
manag
icu
data
concern
demograph
underli
diseas
hsct
summar
tabl
overal
pneumoniarel
mortal
cohort
mortal
relat
ongo
pneumonia
cohort
influenc
neither
posit
neg
microbiolog
result
bal
p
type
agent
p
agranulocytosi
p
signific
mortal
predictor
prior
hsct
p
independ
bal
result
posit
versu
neg
microbiolog
result
p
obtain
balf
sampl
microorgan
found
overal
patient
icu
nonicu
patient
receiv
previou
empir
atb
treatment
accord
current
practic
describ
p
probabl
infecti
pathogen
detect
sampl
classifi
colon
fig
noninfecti
caus
respiratori
complic
diagnos
via
bal
procedur
diagnost
yield
differ
nonneutropen
neutropen
patient
p
also
signific
differ
pathogen
detect
two
group
bacteri
p
fungal
p
viral
p
monomicrobialpolymicrobi
p
signific
differ
balf
find
among
icu
versu
nonicu
patient
except
aspergillu
spp
icu
patient
show
higher
posit
versu
p
fob
bal
gener
well
toler
safe
seriou
advers
reaction
observ
procedur
major
bleed
observ
afterward
assum
caus
pathogen
detect
shown
tabl
wherea
detect
colon
agent
present
tabl
etiolog
agent
pneumonia
consid
polymicrobi
case
virus
fungi
occur
copathogen
almost
one
half
occurr
case
resp
detail
regard
shown
tabl
list
specif
copathogen
present
supplementari
tabl
common
copathogen
aspergillu
spp
case
polymicrobi
infect
streptococcu
pneumonia
n
klebsiella
spp
n
pseudomona
aeruginosa
n
multipl
pathogen
found
treat
accordingli
four
balf
sampl
prove
posit
mycobacterium
tuberculosi
although
two
clinic
relev
three
cultur
mycobacterium
avium
posit
pcr
result
mycobacterium
spp
tuberculosi
observ
one
case
met
american
thorac
societi
document
criteria
nontubercul
mycobacteri
pulmonari
diseas
griffith
et
al
diagnosi
confirm
lung
biopsi
aspergillu
spp
common
agent
detect
bal
sampl
nonneutropen
n
neutropen
patient
n
cohort
detect
case
probableproven
ia
clinic
diagnosi
analyz
gm
signific
balf
sampl
well
median
absorb
index
gm
probableproven
ia
group
rang
significantli
higher
p
median
nonaspergillosi
group
rang
area
roc
curv
auc
bal
gm
index
ci
see
fig
total
p
jirovecii
dna
posit
bal
sampl
median
cpml
rang
cpml
clinic
present
quantiti
p
jirovecii
dna
copi
bal
sampl
radiograph
present
gener
trigger
specif
pcp
treatment
patient
see
fig
median
dna
quantiti
balf
sampl
among
pcp
patient
group
cpml
rang
significantli
higher
p
compar
nonpcp
group
cpml
rang
subsequ
cpml
calcul
threshold
associ
pcp
diagnosi
show
excel
sensit
confid
interv
ci
specif
ci
area
roc
curv
auc
threshold
ci
see
fig
microorgan
detect
analyz
balf
sampl
slightli
higher
previou
recent
report
abl
detect
sampl
bissing
et
al
kim
et
al
hardak
et
al
differ
could
due
wider
rang
microorgan
includ
standard
balf
detect
import
point
major
bal
procedur
done
initi
atb
treatment
icu
patient
nonicu
patient
similar
situat
report
center
rano
et
al
boersma
et
al
hummel
et
al
kuehnhardt
et
al
therefor
result
could
neg
influenc
ongo
antimicrobi
treatment
result
lower
diagnost
yield
balf
cultur
kuehnhardt
et
al
potenti
infecti
pathogen
detect
bal
sampl
publish
studi
report
valu
accur
comparison
variou
report
somewhat
complic
heterogen
laboratori
method
eg
convent
cultur
versu
molecular
method
differ
definit
pathogen
patient
cohort
prior
atb
treatment
hohenadel
et
al
rano
et
al
boersma
et
al
maschmey
et
al
assum
slightli
higher
detect
rate
potenti
pathogen
relat
combin
differ
diagnost
techniqu
one
sampl
includ
molecular
biolog
method
two
recent
studi
tang
et
al
oren
et
al
use
molecular
analysi
prove
infecti
etholog
pneumonia
bal
procedur
similar
studi
statist
differ
pathogen
detect
bal
sampl
neutropen
nonneutropen
cohort
similar
result
also
report
author
cordonni
et
al
kuehnhardt
et
al
rel
minor
differ
group
might
attribut
fact
nonneutropen
patient
immunocompromis
undergon
chemotherapi
previou
episod
neutropenia
even
nonneutropen
time
bal
collect
kuehnhardt
et
al
detect
aspergillu
spp
method
frequent
icu
patient
fact
aspergillu
common
find
balf
icu
patient
previous
report
zarrinfar
et
al
khodavaisi
et
al
might
reflect
overal
sever
icu
patient
etiolog
agent
pneumonia
consid
polymicrobi
case
incid
pulmonari
polymicrobi
infect
patient
hematolog
malign
pulmonari
infiltr
vari
rolston
et
al
hardak
et
al
wide
rang
like
due
differ
definit
bacteri
viral
pneumonia
well
differ
laboratori
method
israel
studi
oren
et
al
includ
pcr
method
report
proport
polymicrobi
pneumonia
similar
patient
cohort
recent
beij
studi
tang
et
al
use
variou
flexibl
bronchoscopi
method
determin
polymicrobi
etiolog
case
contrast
work
work
also
describ
virus
common
infecti
etiolog
pneumonia
result
influenc
patient
cohort
allogen
hsct
recipi
differ
definit
infecti
pneumonia
well
differ
pcr
diagnost
criteria
much
lower
cutoff
signific
pcr
dna
cmv
quantiti
balf
larger
diagnost
spectrum
includ
ebv
polyomaviru
other
anoth
work
focus
hsct
recipi
admit
icu
describ
polymicrobi
find
patient
work
result
blood
cultur
low
pcr
dna
cmv
cutoff
serum
gm
differ
explain
higher
report
percentag
polymicrobi
etiolog
pneumonia
categor
pathogeniccolon
agent
align
updat
guidelin
german
societi
hematolog
medic
oncolog
maschmey
et
al
microbiolog
agent
isol
balf
sampl
alway
relev
etiolog
pulmonari
infiltr
therefor
interpret
critic
maschmey
et
al
report
coagulaseneg
staphylococci
alphahemolyt
streptococci
enterococci
common
bacteria
found
balf
sampl
author
eriksson
et
al
kuehnhardt
et
al
signific
organ
obtain
bal
sampl
remain
unclear
occur
commens
rare
caus
pneumonia
kuehnhardt
et
al
howev
author
suggest
immunocompromis
patient
develop
pneumonia
agent
regardless
kuehnhardt
et
al
bacteria
abund
mouth
oropharynx
adher
bronchoscop
examin
therefor
consid
contaminatingcolon
agent
similar
manner
detect
anaerob
bacteria
consid
contamin
oral
flora
sinc
none
patient
lung
abscess
streptococcu
pneumonia
second
frequent
pathogen
aspergillu
spp
base
pcr
detect
pneumonia
one
common
caus
pneumonia
gener
popul
stralin
et
al
murdoch
et
al
falguera
et
al
preval
immunosuppress
patient
high
kumar
et
al
torda
et
al
wieruszewski
et
al
kumar
et
al
pneumonia
detect
rate
convent
diagnost
method
low
especi
case
antibiot
therapi
administr
examin
et
al
smith
et
al
yu
et
al
pcr
detect
method
may
therefor
use
howev
rel
low
specif
posit
predict
valu
pneumonia
use
nonsteril
materi
balf
may
inflat
incid
rate
cohort
aspergillu
spp
commonli
detect
agent
studi
consist
report
author
oren
et
al
tang
et
al
rano
et
al
boersma
et
al
hardak
et
al
set
cutoff
valu
bal
gm
index
obtain
excel
specif
sensit
consist
studi
bergeron
et
al
maerten
et
al
zygomycosi
second
frequent
detect
filament
fungi
recent
describ
one
common
type
mycosi
report
patient
hematolog
malign
particularli
acut
leukemia
patient
hsct
recipi
caira
et
al
cuencaestrella
et
al
observ
six
posit
qpcr
hit
zygomycet
studi
six
patient
treat
zygomycosi
highrisk
patient
clinic
sign
consist
invas
fungal
diseas
two
qpcr
hit
also
confirm
bal
cultur
meet
criteria
probabl
fungal
diseas
per
eortc
criteria
de
pauw
et
al
remain
four
classifi
possibl
histopatholog
confirm
invas
zygomycosi
requir
siwek
et
al
stelzmuel
et
al
howev
none
avail
patient
despit
awar
potenti
high
fals
posit
rate
firmli
believ
use
qpcr
test
consid
zygomycet
one
diagnost
criteria
calcul
threshold
qpcr
detect
p
jirovecii
estim
cutoff
valu
cpml
valu
obtain
retrospect
analysi
patient
hematolog
malign
correspond
heterogen
immunocompromis
patient
cohort
report
et
al
must
highlight
pcr
valu
vari
significantli
among
center
due
differ
procedur
sampl
collect
differ
qpcr
kit
primer
calibr
curv
therefor
valu
directli
appli
center
differ
setup
one
largest
studi
establish
cutoff
aspergillu
gm
pcr
pcp
deal
larg
cohort
real
world
patient
therefor
confirm
clinic
valu
cutoff
prophylaxi
hsv
infect
acyclovir
contribut
current
decreas
preval
hsv
pneumon
highrisk
patient
azoulay
evid
hsv
qpcr
hit
observ
bal
sampl
similar
report
goosken
et
al
diagnosi
hsv
pneumonia
need
confirm
isol
viru
respiratori
secret
either
balf
sampl
lung
tissu
demonstr
viral
cytopath
effect
histopatholog
azoulay
molecular
detect
techniqu
may
sensit
detect
hsv
lung
asymptomat
individu
goosken
et
al
agusti
torr
oral
contamin
follow
mucos
reactiv
may
also
play
role
hsv
detect
balf
sampl
goosken
et
al
clinic
relev
dna
threshold
bal
sampl
determin
differ
accord
refer
studi
goosken
et
al
linssen
et
al
conclud
publish
quantiti
compar
cpml
balf
sampl
therefor
valu
use
threshold
determin
signific
regardless
conclus
data
found
prove
best
possibl
valu
thu
studi
would
need
determin
specif
qpcr
threshold
hsv
bal
sampl
detect
rate
cmv
posit
bal
studi
differ
joo
et
al
kuehnhardt
et
al
howev
diagnost
method
differ
evid
cmv
dna
bal
sampl
low
posit
predict
valu
boeckh
maschmey
et
al
regard
viral
load
bal
sampl
associ
cmv
pneumon
solid
organ
transplant
recipi
studi
contradictori
result
tan
et
al
could
correl
viral
load
cmv
pneumonia
defin
ljungman
et
al
final
diagnosi
confirm
case
cohort
base
expert
panel
discuss
cp
cmv
dnaml
per
balf
sampl
consid
clinic
signific
patient
cmv
dna
quantiti
balf
sampl
gener
lower
cpml
neg
viral
load
peripher
blood
time
bal
collect
although
pneumonia
detect
human
rhinovirus
hrv
infect
report
immunocompromis
patient
well
still
uncertain
whether
rhinovirus
actual
primari
caus
pneumonia
lead
pulmonari
injuri
andor
superinfect
malcolm
et
al
chemali
et
al
parodi
et
al
malcolm
et
al
parodi
et
al
mention
common
appear
picornavirus
ongo
copathogen
eight
hrv
find
associ
copathogen
well
bacteria
virus
aspergilli
howev
result
studi
base
qpcr
method
balf
sampl
real
signific
find
remain
unclear
observ
pneumonia
mortal
rate
studi
hardak
et
al
refer
overal
valu
inhospit
mortal
rate
us
howev
mortal
patient
polymicrobi
pneumonia
higher
monomicrobi
infect
versu
contrari
observ
patient
cohort
similar
strict
criteria
use
definit
bacteri
viral
pneumonia
hardak
work
may
play
crucial
role
observ
differ
hand
kuehnhardt
et
al
report
mortal
relat
pneumonia
cohort
examin
contain
allogen
hsct
recipi
compar
may
explain
mortal
differ
multipl
factor
contribut
high
mortal
morbid
hsct
recipi
pulmonari
complic
eg
b
cell
statu
reconstitut
hsct
immunosuppress
therapi
degre
neutropenia
presenc
grade
graft
versu
host
diseas
treatment
statu
hematolog
diseas
time
hsct
retrospect
charact
work
allow
larg
patient
cohort
also
drawback
balf
result
avail
quickli
hour
direct
microscopi
examin
pcr
method
take
day
week
eg
day
fungal
cultur
week
mycobacteria
cultiv
imposs
retrospect
work
find
whether
chang
antimicrobi
treatment
base
mainli
bal
result
chang
patient
clinic
statu
along
examin
result
henc
analyz
import
unbias
outcom
mortal
remain
undetermin
whether
act
balf
result
reduc
mortal
rate
mortal
relat
ongo
pneumonia
cohort
influenc
posit
neg
microbiolog
result
bal
type
agent
agranulocytosi
signific
mortal
predictor
prior
hsct
p
independ
bal
result
beij
work
tang
et
al
studi
impact
flexibl
bronchoscopi
patient
allogen
hsct
show
differ
mortal
patient
posit
neg
fb
group
rano
et
al
demonstr
decreas
mortal
rate
treatment
adjust
soon
possibl
base
result
earli
diagnost
combin
sever
method
includ
bal
anoth
studi
kuehnhardt
et
al
describ
chang
antibiot
treatment
base
bal
result
minor
patient
differ
mortal
rate
sever
limit
studi
note
first
retrospect
design
collect
clinic
data
larg
cohort
patient
allow
us
accur
comment
detail
paramet
antimicrobi
treatment
blood
count
avail
day
bal
collect
could
evalu
impact
potenti
prolong
neutropenia
kuehnhardt
et
al
import
limit
also
lack
histolog
evid
support
specif
type
pneumonia
eg
ia
pcp
summari
balf
examin
reveal
infecti
etiolog
pneumonia
patient
hematolog
malign
contribut
key
find
individu
case
especi
specif
treatment
may
administ
one
third
case
classifi
colon
noninfecti
diseas
studi
still
need
determin
specif
qpcr
threshold
opportunist
pathogen
bal
